Publicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (17)

2021

  1. HLA–B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 963-969

2020

  1. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

    Scientific Reports, Vol. 10, Núm. 1

  2. Publisher Correction: A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis (Scientific Reports, (2020), 10, 1, (3355), 10.1038/s41598-020-60305-x)

    Scientific Reports

2019

  1. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

  2. Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339

2018

  1. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial

    American Journal of Ophthalmology, Vol. 195, pp. 181-190

2015

  1. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2013

  1. Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy

    Journal of Rheumatology, Vol. 40, Núm. 11, pp. 1850-1855

2011

  1. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists

    Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 1, pp. 71-80

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 4, pp. 579-583

  3. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

  4. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564

2008

  1. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1

2003

  1. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report

    Arthritis and Rheumatism, Vol. 48, Núm. 8, pp. 2122-2127